Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of non-psychoactive cannabinoid (“CBD”) and synthetic CBD medicines intended to address the unmet needs of large patient populations, today announced it has appointed Ronald P. Erickson to its Board of Directors.
Ronald Erickson is a senior business executive with more than 30 years of experience in the pharmaceutical, technology, telecom and digital media industries. He is the Founder, CEO, President and Chairman of Visualant, Inc. (OTCQB: VSUL), a developer of unique spectral pattern matching technology. Mr. Erickson also sits on a number of corporate boards including Bioasis Technologies (OTCQB: BIOAF), a biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier.
“Ron Erickson is a savvy business executive who brings a wealth of contacts and experience building and running developmental and emerging-growth stage companies in a variety of industries including early-stage pharmaceutical,” said Seth Yakatan, Kalytera CEO. “Ron fills an important niche in our Board composition and I am delighted to welcome him to Kalytera.”
Commenting on his appointment to the Kalytera Board, Mr. Erickson said, “Kalytera’s pioneering work with its unique CBD derivative compounds is exciting and opens up an under-explored category of drug therapy that could serve to more effectively treat a number of common, chronic diseases worldwide. I am pleased to join the Kalytera team, and excited at the prospect of helping to advance its important work in pharmaceutical science.”
Ronald P. Erickson Bio
Ronald Erickson is a senior business executive with more than 30 years of experience in the pharmaceutical, technology, telecom and digital media industries. He is the founder of Visualant, Inc. (OTCQB: VSUL), a developer of unique spectral pattern matching technology. He has served as a director and officer of Visualant since April 2003, and was appointed CEO and President in November 2009 and Chairman of the Board in February 2015. Mr. Erickson also sits on a number of corporate boards including Bioasis Technologies (OTCQB: BIOAF), a biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier and into the brain tissue.
He is formerly Chairman, CEO and Co-Founder of Blue Frog Media, a mobile media and entertainment company; Chairman and CEO of eCharge Corporation, an Internet-based transaction procession company; Chairman, CEO and Co-founder of GlobalTel Resources, a provider of telecommunications services; Chairman, Interim President and CEO of Egghead Software, Inc., a software reseller where he was an original investor; Chairman and CEO of NBI, Inc.; and Co-founder of MicroRim, Inc., the database software developer.
Earlier, Mr. Erickson practiced law in Seattle and worked in public policy in Washington, D.C. and New York City. Additionally, he has been an angel investor and board member of a number of public and private technology companies. In addition to his business activities, Mr. Erickson serves on the Board of Trustees of Central Washington University where he received his B.A. degree. He also holds an M.A. from the University of Wyoming and a J.D. from the University of California, Davis and is licensed to practice law in the State of Washington.
Kalytera Therapeutics, Inc. is a pharmaceutical company that is developing a portfolio of nonpsychoactive cannabinoid and cannabinoid-modulating medicines that address the unmet needs of large patient populations. The Company seeks to commercialize its proprietary, synthetic cannabinoid therapies across a range of disease states, with an initial focus on bone healing and osteoporosis. For more information, visit: https://kalytera.co/.
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management’s estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of Kalytera. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to Kalytera cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, Kalytera will not obtain appropriate or necessary governmental approvals to market these or other potential products, Kalytera may not be able to obtain anticipated funding for its development projects or other needed funding, and Kalytera may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and Kalytera does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.